Evidence map›Paper›PMID 35667316›Full record

ArticleMultiple sclerosis and related disorders2022

Longitudinal humoral response in MS patients treated with cladribine tablets after receiving the second and third doses of SARS-CoV-2 mRNA vaccine.

Livnat Brill, Ariel Rechtman, Alla Shifrin, Ayal Rozenberg, Svetlana Afanasiev, Omri Zveik, Nitzan Haham, Neta Levin, Adi Vaknin-Dembinsky

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Multiple sclerosis and related disorders, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Livnat BrillDepartment of Neurology and Laboratory of Neuroimmunology and the Agnes-Ginges Center for Neurogenetics, Hadassah- Medical Center. Faculty of Medicine, Hebrew University of Jerusalem. Jerusalem, Israel.
Ariel RechtmanDepartment of Neurology and Laboratory of Neuroimmunology and the Agnes-Ginges Center for Neurogenetics, Hadassah- Medical Center. Faculty of Medicine, Hebrew University of Jerusalem. Jerusalem, Israel.
Alla ShifrinDepartment of Neurology, Rambam Health Care Campus and Technion Faculty of Medicine, Haifa, Israel.
Ayal RozenbergDepartment of Neurology, Rambam Health Care Campus and Technion Faculty of Medicine, Haifa, Israel.
Svetlana AfanasievDepartment of Neurology, Rambam Health Care Campus and Technion Faculty of Medicine, Haifa, Israel.
Omri ZveikDepartment of Neurology and Laboratory of Neuroimmunology and the Agnes-Ginges Center for Neurogenetics, Hadassah- Medical Center. Faculty of Medicine, Hebrew University of Jerusalem. Jerusalem, Israel.
Nitzan HahamDepartment of Neurology and Laboratory of Neuroimmunology and the Agnes-Ginges Center for Neurogenetics, Hadassah- Medical Center. Faculty of Medicine, Hebrew University of Jerusalem. Jerusalem, Israel.
Neta LevinFunctional Imaging Unit, Department of Neurology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.
Adi Vaknin-DembinskyDepartment of Neurology and Laboratory of Neuroimmunology and the Agnes-Ginges Center for Neurogenetics, Hadassah- Medical Center. Faculty of Medicine, Hebrew University of Jerusalem. Jerusalem, Israel.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMultiple sclerosis (MS) patients receive immunomodulatory treatments which can influence their ability to maintain vaccine specific serological response overtime. MS patients treated with cladribine tablets developed a positive serology response following two doses of mRNA COVID-19 vaccine. However, there is only limited data regarding the effect of cladribine tablets on long-term humoral response after the second and the third booster.

methodsSerology response to SARS-CoV-2 was tested in healthy controls (HCs) and MS patients treated with cladribine tablets 6 and 9-12 months after the second dose, and 1 and 3-6 months following the third booster-dose of the BTN162b2 mRNA vaccine.

resultsThirty-five out of 36 MS patients treated with cladribine tablets and 100% (46/46) of HCs had a positive serology response up to 10 months after the second vaccine dose. In addition, all cladribine tablets -treated MS patients (22/22) and HCs (24/24) had a positive robust serology response following the third vaccine with a positive humoral response sustain up to 6 months. One month after the third vaccine dose IgG levels were significantly lower in patients treated with cladribine tablets compared to HCs (15,598+11,313 vs 26,394+11,335, p<0.01). Six-month post second vaccine and 3-6 months post third vaccine there was no difference in IgG levels between the groups (1088.0 ± 1072.0 vs 1153.0 ± 997.1, p = 0.79; 5234+4097 vs 11,198+14,679, p = 0.4). CONCLUSION AND RELEVANCE: MS patients treated with cladribine tablets have sustained positive vaccine specific serology response following the second and third SARS-CoV-2 vaccine dose.

Indexed as

COVID-19Multiple SclerosisMultiple Sclerosis, Relapsing-RemittingAntibodies, ViralCladribineCOVID-19 VaccinesHumansImmunoglobulin GImmunosuppressive AgentsmRNA VaccinesSARS-CoV-2TabletsVaccines, SyntheticAntibodies, ViralCladribineCOVID-19 VaccinesImmunoglobulin GImmunosuppressive AgentsmRNA VaccinesTabletsVaccines, SyntheticCladribine tabletsCOVID-19 vaccinationLong term serology responseMultiple sclerosis

Identifiers

PMID35667316
PMCPMC9088160

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.